Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonafarnib + Paclitaxel + Carboplatin in NSCLC
NCT00050336Phase 3
Key facts
- Status
- Terminated
- Start
- Dec 2002
- Primary completion
- Feb 2004
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Drugs
- lonafarnib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Lonafarnib Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival. Started Dec 2002; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Lonafarnib Arm
Lonafarnib in combination with Paclitaxel and Carboplatin
Placebo Arm
Placebo in combination with Paclitaxel and Carboplatin
03
Who it enrols
Patients with stage 3b or 4 NSCLC, ECOG 0-1, no prior chemotherapy, and adequate organ function.
04
Endpoints
Primary
Overall Survival
Beyond the preview
Go deeper on NCT00050336.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050336.